Lysyl Oxidase Is Downregulated by the EWS/FLI1 Oncoprotein and Its Propeptide Domain Displays Tumor Supressor Activities in Ewing Sarcoma Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Agra, Noelia ^a   Cidre, Florencia ^a   García García, Laura ^a   de la Parra, Juan ^a   Alonso, Javier ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXYCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN LYSINE 6 OXIDASE; PROTEIN LYSINE 6 OXIDASE PROPEPTIDE; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL ANCHORAGE; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; EWING SARCOMA; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIMARY TUMOR; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; SARCOMA CELL; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; HUMANS; MICE; ONCOGENE PROTEINS, FUSION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-LYSINE 6-OXIDASE; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 84878663317     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066281     Document Type: Article

References (59)

1. Potratz J, Dirksen U, Jurgens H, Craft A, (2012) Ewing Sarcoma: Clinical State-of-the-Art. Pediatr Hematol Oncol 29: 1-11.
2. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J, (2009) Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res 69: 7140-7150.
3. Toomey EC, Schiffman JD, Lessnick SL, (2010) Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene 29: 4504-4516.
4. Mackintosh C, Madoz-Gurpide J, Ordonez JL, Osuna D, Herrero-Martin D, (2010) The molecular pathogenesis of Ewing's sarcoma. Cancer Biol Ther 9: 655-667.
5. Kovar H, (2010) Downstream EWS/FLI1- upstream Ewing's sarcoma. Genome Med 2: 8.
6. Lessnick SL, Ladanyi M (2011) Molecular Pathogenesis of Ewing Sarcoma: New Therapeutic and Transcriptional Targets. Annu Rev Pathol.
7. Grunewald TG, Diebold I, Esposito I, Plehm S, Hauer K, et al. (2012) STEAP1 Is Associated with the Invasive and Oxidative Stress Phenotype of Ewing Tumors. Mol Cancer Res 10: 52-65.
8. Carrillo J, Garcia-Aragoncillo E, Azorin D, Agra N, Sastre A, et al. (2007) Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth. Clin Cancer Res 13: 2429-2440.
9. Garcia-Aragoncillo E, Carrillo J, Lalli E, Agra N, Gomez-Lopez G, et al. (2008) DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. Oncogene 27: 6034-6043.
10. Herrero-Martin D, Osuna D, Ordonez JL, Sevillano V, Martins AS, et al. (2009) Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br J Cancer 101: 80-90.
11. Prieur A, Tirode F, Cohen P, Delattre O, (2004) EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24: 7275-7283.
12. Tirado OM, Mateo-Lozano S, Villar J, Dettin LE, Llort A, et al. (2006) Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res 66: 9937-9947.
13. Mendiola M, Carrillo J, Garcia E, Lalli E, Hernandez T, et al. (2006) The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. Int J Cancer 118: 1381-1389.
14. Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, et al. (2011) Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene 30: 2173-2180.
15. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, et al. (2009) EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A 106: 5324-5329.
16. Ban J, Bennani-Baiti IM, Kauer M, Schaefer KL, Poremba C, et al. (2008) EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res 68: 7100-7109.
17. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, et al. (2006) Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 9: 405-416.
18. Kinsey M, Smith R, Lessnick SL, (2006) NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 4: 851-859.
19. Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, et al. (2009) GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 28: 4126-4132.
20. Navarro D, Agra N, Pestana A, Alonso J, Gonzalez-Sancho JM, (2010) The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription. Carcinogenesis 31: 394-401.
21. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, et al. (1993) The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 13: 7393-7398.
22. Bailly RA, Bosselut R, Zucman J, Cormier F, Delattre O, et al. (1994) DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 14: 3230-3241.
23. Nakatani F, Tanaka K, Sakimura R, Matsumoto Y, Matsunobu T, et al. (2003) Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 278: 15105-15115.
24. Hahm KB, Cho K, Lee C, Im YH, Chang J, et al. (1999) Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 23: 222-227.
25. Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, et al. (2012) Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene.
26. Owen LA, Kowalewski AA, Lessnick SL, (2008) EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS One 3: e1965.
27. De Vito C, Riggi N, Suva ML, Janiszewska M, Horlbeck J, et al. (2011) Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development. PLoS One 6: e23592.
28. Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, et al. (2012) miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 226: 796-805.
29. Lucero HA, Kagan HM, (2006) Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci 63: 2304-2316.
30. Molnar J, Fong KS, He QP, Hayashi K, Kim Y, et al. (2003) Structural and functional diversity of lysyl oxidase and the LOX-like proteins. Biochim Biophys Acta 1647: 220-224.
31. Kagan HM, Li W, (2003) Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 88: 660-672.
32. Smith-Mungo LI, Kagan HM, (1998) Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol 16: 387-398.
33. Palamakumbura AH, Jeay S, Guo Y, Pischon N, Sommer P, et al. (2004) The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem 279: 40593-40600.
34. Min C, Kirsch KH, Zhao Y, Jeay S, Palamakumbura AH, et al. (2007) The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer. Cancer Res 67: 1105-1112.
35. Wu M, Min C, Wang X, Yu Z, Kirsch KH, et al. (2007) Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer Res 67: 6278-6285.
36. Navarro D, Agra N, Pestana A, Alonso J, Gonzalez-Sancho JM, (2010) The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription. Carcinogenesis 31: 394-401.
37. Duvic M, Vu J, (2007) Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16: 1111-1120.
38. Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, et al. (2003) DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33: 61-65.
39. Hurtado PA, Vora S, Sume SS, Yang D, St Hilaire C, et al. (2008) Lysyl oxidase propeptide inhibits smooth muscle cell signaling and proliferation. Biochem Biophys Res Commun 366: 156-161.
40. Vora SR, Guo Y, Stephens DN, Salih E, Vu ED, et al. (2010) Characterization of recombinant lysyl oxidase propeptide. Biochemistry 49: 2962-2972.
41. Guo Y, Pischon N, Palamakumbura AH, Trackman PC, (2007) Intracellular distribution of the lysyl oxidase propeptide in osteoblastic cells. Am J Physiol Cell Physiol 292: C2095-2102.
42. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
43. Kauer M, Ban J, Kofler R, Walker B, Davis S, et al. (2009) A molecular function map of Ewing's sarcoma. PLoS One 4: e5415.
44. Hancock JD, Lessnick SL, (2008) A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 7: 250-256.
45. Kuivaniemi H, Korhonen RM, Vaheri A, Kivirikko KI, (1986) Deficient production of lysyl oxidase in cultures of malignantly transformed human cells. FEBS Lett 195: 261-264.
46. Bouez C, Reynaud C, Noblesse E, Thepot A, Gleyzal C, et al. (2006) The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. Clin Cancer Res 12: 1463-1469.
47. Hamalainen ER, Kemppainen R, Kuivaniemi H, Tromp G, Vaheri A, et al. (1995) Quantitative polymerase chain reaction of lysyl oxidase mRNA in malignantly transformed human cell lines demonstrates that their low lysyl oxidase activity is due to low quantities of its mRNA and low levels of transcription of the respective gene. J Biol Chem 270: 21590-21593.
48. Csiszar K, Fong SF, Ujfalusi A, Krawetz SA, Salvati EP, et al. (2002) Somatic mutations of the lysyl oxidase gene on chromosome 5q23.1 in colorectal tumors. Int J Cancer 97: 636-642.
49. Ren C, Yang G, Timme TL, Wheeler TM, Thompson TC, (1998) Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res 58: 1285-1290.
50. Kenyon K, Contente S, Trackman PC, Tang J, Kagan HM, et al. (1991) Lysyl oxidase and rrg messenger RNA. Science 253: 802.
51. Hajnal A, Klemenz R, Schafer R, (1993) Up-regulation of lysyl oxidase in spontaneous revertants of H-ras-transformed rat fibroblasts. Cancer Res 53: 4670-4675.
52. Jeay S, Pianetti S, Kagan HM, Sonenshein GE, (2003) Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. Mol Cell Biol. 23: 2251-2263.
53. Giampuzzi M, Botti G, Cilli M, Gusmano R, Borel A, et al. (2001) Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of ras proto-oncogene. J Biol Chem 276: 29226-29232.
54. Zhao Y, Min C, Vora SR, Trackman PC, Sonenshein GE, et al. (2009) The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. J Biol Chem 284: 1385-1393.
55. Palamakumbura AH, Vora SR, Nugent MA, Kirsch KH, Sonenshein GE, et al. (2009) Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. Oncogene 28: 3390-3400.
56. Min C, Zhao Y, Romagnoli M, Trackman PC, Sonenshein GE, et al. (2010) Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis. J Cell Biochem 111: 1160-1168.
57. Navarro S, Gonzalez-Devesa M, Ferrandez-Izquierdo A, Triche TJ, Llombart-Bosch A, (1990) Scanning electron microscopic evidence for neural differentiation in Ewing's sarcoma cell lines. Virchows Arch A Pathol Anat Histopathol 416: 383-391.
58. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, et al. (1994) A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 6: 146-151.
59. Abramoff MD, Magalhaes PJ, Ram SJ, (2004) Image processing with ImageJ. Biophotonics International 11: 36-42.